Related Experiment Videos
Ductal carcinoma in situ
1Department of Surgery, Feinberg School of Medicine of Northwestern University, 676 North St. Clair Street, Galter 13-174, Chicago, IL 61611, USA.
The Surgical Clinics of North America
|July 24, 2003
Summary
Ductal carcinoma in situ (DCIS) is a complex breast condition. Current methods cannot predict which DCIS cases will not progress, highlighting the need for further research into its natural history and improved patient counseling for treatment decisions.
Area of Science:
- Oncology
- Breast Cancer Research
- Genomics
Background:
- Ductal carcinoma in situ (DCIS) is a heterogeneous non-invasive breast cancer.
- The natural history of DCIS remains poorly understood, making it difficult to predict progression.
- Increased screening mammography has led to higher detection rates of DCIS.
Purpose of the Study:
- To address the uncertainty in identifying clinically insignificant DCIS.
- To explore the role of genomics in understanding DCIS natural history.
- To improve clinical decision-making and patient counseling regarding DCIS treatment options.
Main Methods:
- Review of current understanding of DCIS natural history.
- Discussion of the potential of genomic studies.
- Analysis of treatment variations and decision-making factors.
Main Results:
- Current inability to identify DCIS cases that will not progress to invasive carcinoma.
- Genomics shows promise but requires prospective studies with long-term follow-up.
- Treatment decisions for DCIS vary due to uncertainties and physician values.
Conclusions:
- Further research, particularly prospective genomic studies, is essential to define clinically insignificant DCIS.
- Improved communication of long-term risks, benefits, and quality-of-life trade-offs is crucial for patient-centered DCIS management.
- The extent of DCIS and defined contraindications guide breast-conserving treatment decisions.